![](/images/graphics-bg.png)
Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial
Joint Authors
Gao, Yue-Qiu
Zhang, Jing-Hao
Zheng, Chao
Zhang, Xin
Hou, Zhi-Jun
Wang, Yu-Qing
Wang, Kai-Xia
Yu, Zhuo
Li, Man
Zhou, Zheng-Hua
Sun, Xue-Hua
Zhu, Xiao-Jun
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-19
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Objective.
To ascertain the efficacy and safety of Ganji Formulation (GF) for patients with Hepatocellular carcinoma (HCC) who had undergone surgery.
Materials and Methods.
A total of 262 HCC patients who had undergone liver resection, local ablation, or transcatheter arterial chemoembolization (TACE) were divided randomly into the treatment group and control group.
The former was treated with GF and the later with placebo, both for 6 months.
The primary endpoint was overall survival (OS).
Second endpoints were disease-free survival (DFS) or time to disease progression (TTP).
Results.
OS of the treatment group was significantly longer than that of the control group (P < 0.05).
Subgroup analysis showed that, for patients who received TACE, the TTP was significantly longer in the treatment group than in the control group (P < 0.05).
However, for patients who underwent liver resection or local ablation, there was no significant difference in DFS between the two groups (P > 0.05).
Conclusion.
GF could improve postoperative cumulative survival and prolong the TTP.
This clinical trial number is registered with ChiCTR-IOR-15007349.
American Psychological Association (APA)
Zhang, Jing-Hao& Zheng, Chao& Zhu, Xiao-Jun& Zhang, Xin& Hou, Zhi-Jun& Zhou, Zheng-Hua…[et al.]. 2019. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
Modern Language Association (MLA)
Zhang, Jing-Hao…[et al.]. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
American Medical Association (AMA)
Zhang, Jing-Hao& Zheng, Chao& Zhu, Xiao-Jun& Zhang, Xin& Hou, Zhi-Jun& Zhou, Zheng-Hua…[et al.]. Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1151732
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1151732